MYRIAD GENETICS INC Action · US62855J1043 · MYGN · 897518 (XNAS) — cotations en temps réel, données d'entreprise, dividendes, fondamentaux et analyse de portefeuille IA sur MoneyPeak

Aperçu

Analyse alimentée par l’IA

Analyse fondamentale

Découvrez ce que disent vraiment les chiffres — avant le marché

Analyser maintenant

Sentiment des actualités

Les actualités d’aujourd’hui sont-elles un signal d’achat ou un avertissement ?

Analyser maintenant

Acheter / Conserver / Vendre

Faut-il acheter, conserver ou vendre ? Obtenez l’avis de l’IA dès maintenant.

Analyser maintenant

Évaluation des risques

Détectez les risques cachés avant qu’ils n’impactent votre portefeuille.

Analyser maintenant

Juste valeur

Cette action est-elle bon marché, correctement valorisée ou surévaluée ?

Analyser maintenant

Dernières analyses d’IA sur MYRIAD GENETICS INC

Résumé de la Note des Analystes

Conserver

Achat fort

Achat

Conserver

Vente

Vente forte

Pas de cours

01.05.2026 20:00

Cours actuels de MYRIAD GENETICS INC

Bourse	Ticker	Devise	Dernier échange	Cours	Variation journalière
NASDAQ	MYGN	USD	01.05.2026 20:00	4,80 USD	0,05 USD +1,05 %
IEX	MYGN	USD	01.05.2026 19:59	4,80 USD	0,05 USD +1,05 %
London	0K3W.L	USD	01.05.2026 14:17	4,89 USD	0,14 USD +2,95 %
Düsseldorf	MGIRSD43.DUSB	EUR	30.04.2026 17:31	4,01 EUR	-
Hannover	MGIRSD43.HANB	EUR	30.04.2026 15:25	4,05 EUR	-
Hamburg	MGIRSD43.HAMB	EUR	30.04.2026 15:25	4,05 EUR	-
Quotrix	MGIRSD43.DUSD	EUR	30.04.2026 05:27	3,99 EUR	-

Flottant et Liquidité des Actions

Flottant Libre 93,17 %

Actions en Flottant 87,12 M

Actions en Circulation 93,51 M

Fonds investis

Les fonds suivants ont investi dans MYRIAD GENETICS INC :

Fonds iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)	Vol. en millions 93,30	Part (%) 0,22 %

Profil de l'entreprise pour MYRIAD GENETICS INC Action

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.